- Home
- AUTL vs ZVRA Comparison
AUTL vs ZVRA Comparison
Compare AUTL & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | ZVRA |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.8M | 502.7M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AUTL | ZVRA |
|---|---|---|
| Price | $1.42 | $8.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $8.33 | ★ $21.71 |
| AVG Volume (30 Days) | ★ 2.1M | 969.7K |
| Earning Date | 03-19-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | $51,128,000.00 | ★ $84,388,000.00 |
| Revenue This Year | $672.42 | $333.64 |
| Revenue Next Year | $84.48 | $44.19 |
| P/E Ratio | ★ N/A | $16.00 |
| Revenue Growth | ★ 406.67 | 244.60 |
| 52 Week Low | $1.11 | $6.19 |
| 52 Week High | $2.70 | $13.16 |
Technical Indicators
Market Signals| Indicator | AUTL | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.18 | 46.15 |
| Support Level | $1.31 | $8.32 |
| Resistance Level | $1.45 | $9.62 |
| Average True Range (ATR) | 0.07 | 0.50 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 18.37 | 22.69 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.